<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[RSS Feed]]></title><description><![CDATA[RSS Feed]]></description><link>https://ecency.com</link><image><url>https://ecency.com/logo512.png</url><title>RSS Feed</title><link>https://ecency.com</link></image><generator>RSS for Node</generator><lastBuildDate>Sat, 22 Aug 2026 11:08:21 GMT</lastBuildDate><atom:link href="https://ecency.com/created/a215600/rss.xml" rel="self" type="application/rss+xml"/><item><title><![CDATA[신라젠 매수권 진입]]></title><description><![CDATA[신라젠은 다음달(4월) 9~12일 영국 옥스퍼드에서 열리는 국제 종양파괴 바이러스 컨퍼런스 2018(International Oncolytic Virus Conference 2018)에서 신장암 환자를 대상으로 펙사벡을 투여한 임상 2상 연구결과를 발표한다고 13일 밝혔다. 뉴스링크]]></description><link>https://ecency.com/@halfpoint/6uan8c</link><guid isPermaLink="true">https://ecency.com/@halfpoint/6uan8c</guid><category><![CDATA[a215600]]></category><dc:creator><![CDATA[halfpoint]]></dc:creator><pubDate>Wed, 04 Apr 2018 02:00:39 GMT</pubDate><enclosure url="https://i.ecency.com/p/9rkh8ncQmjYmu9XT1uep1dfJRSVduAPkUxm7f7NCmkH8c6FVddpboFQNXqQebWfDisAd6f8McEr3FeWgkNm8mPfK4thQspjRSBRcKFBhFLc2DboAbQb9aqyqSHQLokdi8QcrdeGkvyc12UMbx1kc24tAFG2vZUgknV9MLgvZH1eS4mRSxk9DqrPg59hDDaCQLXsNvSxYZrL4SoL7PJTTeX9He7wao89AoHdCQr3Lwq54RfVPyPgYz2f7qFnkZqCqVa7wy8dNEguNnYNsshtvQQYtndqRVAMg1Rit61J8TGDNygCatBCQuitmN7tGzmszhXMX36sp?format=match&amp;mode=fit" length="0" type="false"/></item></channel></rss>